Biolase Inc.

4.53+0.3100+7.35%Vol 26.67K1Y Perf 474.23%
Jun 24th, 2022 15:58 DELAYED
BID4.50 ASK4.60
Open4.27 Previous Close4.22
Pre-Market- After-Market4.58
 - -  0.05 1.10%
Target Price
17.50 
Analyst Rating
Strong Buy 1.00
Potential %
286.31 
Finscreener Ranking
★★★+     51.37
Insiders Trans % 3/6/12 mo.
-/-/33 
Value Ranking
★★     46.87
Insiders Value % 3/6/12 mo.
-/-/85 
Growth Ranking
     36.82
Insiders Shares Cnt. % 3/6/12 mo.
-/-/81 
Income Ranking
 —    -
Price Range Ratio 52W %
6.09 
Earnings Rating
Buy
Market Cap27.97M 
Earnings Date
11th Aug 2022
Alpha-0.03 Standard Deviation0.32
Beta1.64 

Today's Price Range

4.234.64

52W Range

3.3023.49

5 Year PE Ratio Range

-1.10-1.20

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-0.66%
1 Month
-5.43%
3 Months
1 198.74%
6 Months
1 032.50%
1 Year
474.23%
3 Years
210.27%
5 Years
-3.62%
10 Years
-55.15%

TickerPriceChg.Chg.%
BIOL4.530.31007.35
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
2.00
3.30
0.43
0.77
-5.70
Leverage Ratio 2.10
ProfitabilityValueIndustryS&P 500US Markets
44.90
-28.90
-27.90
-49.30
-34.03
RevenueValueIndustryS&P 500US Markets
41.24M
6.68
-5.14
-8.50
Earnings HistoryEstimateReportedSurprise %
Q01 2022--0.81-
Q04 2021-0.75-0.750.00
Q03 2021-0.75-0.5033.33
Q02 2021-1.00-0.5050.00
Q01 2021-1.25-1.50-20.00
Q04 2020-1.00-1.75-75.00
Q03 2020-0.06-0.21-250.00
Q02 2020-0.19-0.1236.84
Earnings Per EndEstimateRevision %Trend
9/2019 QR-0.210.00-
3/2022 QR-0.0370.00Positive
12/2022 FY-0.10--
12/2022 FY-0.100.00-
Next Report Date11th Aug 2022
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume26.67K
Shares Outstanding6.17K
Shares Float6.09M
Trades Count454
Dollar Volume119.66K
Avg. Volume185.57K
Avg. Weekly Volume25.88K
Avg. Monthly Volume25.87K
Avg. Quarterly Volume504.96K

Biolase Inc. (NASDAQ: BIOL) stock closed at 4.53 per share at the end of the most recent trading day (a 7.35% change compared to the prior day closing price) with a volume of 26.67K shares and market capitalization of 27.97M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 157 people. Biolase Inc. CEO is John R. Beaver.

The one-year performance of Biolase Inc. stock is 474.23%, while year-to-date (YTD) performance is 1061.54%. BIOL stock has a five-year performance of -3.62%. Its 52-week range is between 3.3 and 23.485, which gives BIOL stock a 52-week price range ratio of 6.09%

Biolase Inc. currently has a PE ratio of -2.10, a price-to-book (PB) ratio of 1.37, a price-to-sale (PS) ratio of 0.68, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.08%, a ROC of -29.49% and a ROE of -52.75%. The company’s profit margin is -34.03%, its EBITDA margin is -27.90%, and its revenue ttm is $41.24 Million , which makes it $6.68 revenue per share.

Of the last four earnings reports from Biolase Inc., there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Biolase Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Biolase Inc. is Strong Buy (1), with a target price of $17.5, which is +286.31% compared to the current price. The earnings rating for Biolase Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Biolase Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Biolase Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 34.25, ATR14 : 0.34, CCI20 : -35.57, Chaikin Money Flow : -0.28, MACD : 0.16, Money Flow Index : 46.27, ROC : -3.00, RSI : 56.14, STOCH (14,3) : 60.25, STOCH RSI : 0.81, UO : 43.64, Williams %R : -39.75), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Biolase Inc. in the last 12-months were: John R. Beaver (Buy at a value of $52 850), Jonathan T. Lord (Sold 11 038 shares of value $4 194 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
2 (100.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
1 (100.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Moderate Buy
2.00

Biolase Inc.

Biolase Inc is a US-based medical device company. It develops, manufactures, markets and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products i.e. Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.

CEO: John R. Beaver

Telephone: +1 949 361-1200

Address: 4 Cromwell, Irvine 92618, CA, US

Number of employees: 157

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

66%34%

TipRanks News for BIOL

News

Stocktwits